Conference Coverage: ASCO 2026 – Focus on Lung Cancer
Expert perspectives and strategic insights on the latest therapeutic developments in lung cancer treatment from the ASCO 2026 conference.
June 12, 2026

Faculty Chair
Corey Langer, MD, FACP
University of Pennsylvania, Philadelphia, PA, USA
Faculty Members
Mark Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, USA
Roy Herbst, MD, PhD
Yale School of Medicine, New Haven, CT, USA
Charles Rudin, MD, PhD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Solange Peters, MD, PhD
University of Hospital of Lausanne, Switzerland
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Fusion-positive NSCLC
- EGFR inhibition in lung cancer
- Emerging agents
- Nonclassical mutations
- New agents and combinations for KRAS G12C-mutated NSCLC
- KRAS G12D inhibitors in lung cancer
- New IO-ADC approaches in stage IV NSCLC
- Rescuing relapsed small cell lung cancer
- Attendee key takeaways
Purchase Report
Thank you for your interest in our insights.
Complete the form below to receive additional information.